Harvard University (US)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
157
Publications
1591
Citations
163972
i10-index
510
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
Improved Survival with Ipilimumab in Patients with... | 2010 | 15185 |
Safety, Activity, and Immune Correlates of Anti–PD... | 2012 | 12627 |
Combined Nivolumab and Ipilimumab or Monotherapy i... | 2015 | 8161 |
Overall Survival with Combined Nivolumab and Ipili... | 2017 | 5348 |
Predictive correlates of response to the anti-PD-L... | 2014 | 5235 |
Five-Year Survival with Combined Nivolumab and Ipi... | 2019 | 3712 |
Safety and Tumor Responses with Lambrolizumab (Ant... | 2013 | 3399 |
Guidelines for the Evaluation of Immune Therapy Ac... | 2009 | 3229 |
Nivolumab and Ipilimumab versus Ipilimumab in Untr... | 2015 | 2790 |
Nivolumab versus chemotherapy in patients with adv... | 2015 | 2688 |
Frank Stephen Hodi is a researcher with 1591 publications and 163972 citations. They are affiliated with Harvard University. Their research focuses on . With an h-index of 157, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Frank Stephen Hodi and 250M+ other papers.
Citations per publication by year